Related Experiment Video
Updated: Sep 9, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Sodium glucose co-transporter 2 inhibitors (SGLT2Is) effect on erectile dysfunction (ED) in patients with chronic
Amr Mohamed Shaker1, Nehal Kamal Rakha2, Ahmed Keshk3
1Nephrology Unit, Internal Medicine Department, Faculty of Medicine, Cairo University, Giza, Egypt. amr.shaker@kasralainy.edu.eg.
Background:
ED is commonly encountered among male CKD patients. SGLT2Is were recently recommended as a universal treatment for CKD. It's hypothesized that the mechanism of action of SGLT2Is could be related to improving endothelial dysfunction. So, patients with ED due to CKD might benefit from adding SGLT2Is to their management. We aimed to study the effect of SGLT2Is on ED in CKD patients.
Methods:
After complete clinical examination and laboratory investigations needed to exclude other causes of ED, 34 CKD cases were randomly assigned to receive either empagliflozin (Empa) or dapagliflozin (Dapa). All selected candidates signed a written consent and were then referred to the Andrology clinic for assessment for ED. The structured questionnaire (International Index of Erectile Function) was used before starting and 3 months after use of the assigned SGLT2I.
Results:
Both SGLT2Is were associated with highly significant improvement in kidney function as well as IIEF-5 (P < 0.001 in all).
Conclusion:
SGLT2Is improve endothelial function and correct pericyte depletion induced by uremia. The postulated mechanisms of action that improve erectile function are discussed.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Action of Diuretics
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

